Cargando…

Sirolimus-induced interstitial lung disease and resolution after conversion to everolimus

Mammalian target of rapamycin inhibitors (mTORi) are used to treat a variety of malignancies and have an established role in organ transplantation. Interstitial lung disease (ILD) is one of the complications of mTORi and is believed to be a class effect. More cases of ILD have been reported with sir...

Descripción completa

Detalles Bibliográficos
Autores principales: Alkhunaizi, Ahmed M., Al-Khouzaie, Thamer H., Alsagheir, Ahmed I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7287142/
https://www.ncbi.nlm.nih.gov/pubmed/32551222
http://dx.doi.org/10.1016/j.rmcr.2020.101109
_version_ 1783545006700625920
author Alkhunaizi, Ahmed M.
Al-Khouzaie, Thamer H.
Alsagheir, Ahmed I.
author_facet Alkhunaizi, Ahmed M.
Al-Khouzaie, Thamer H.
Alsagheir, Ahmed I.
author_sort Alkhunaizi, Ahmed M.
collection PubMed
description Mammalian target of rapamycin inhibitors (mTORi) are used to treat a variety of malignancies and have an established role in organ transplantation. Interstitial lung disease (ILD) is one of the complications of mTORi and is believed to be a class effect. More cases of ILD have been reported with sirolimus than with everolimus in the literature, possibly due to earlier introduction and wider use of sirolimus. We report the case of a kidney transplant recipient who developed ILD secondary to sirolimus and improved rapidly after switching to everolimus.
format Online
Article
Text
id pubmed-7287142
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-72871422020-06-17 Sirolimus-induced interstitial lung disease and resolution after conversion to everolimus Alkhunaizi, Ahmed M. Al-Khouzaie, Thamer H. Alsagheir, Ahmed I. Respir Med Case Rep Case Report Mammalian target of rapamycin inhibitors (mTORi) are used to treat a variety of malignancies and have an established role in organ transplantation. Interstitial lung disease (ILD) is one of the complications of mTORi and is believed to be a class effect. More cases of ILD have been reported with sirolimus than with everolimus in the literature, possibly due to earlier introduction and wider use of sirolimus. We report the case of a kidney transplant recipient who developed ILD secondary to sirolimus and improved rapidly after switching to everolimus. Elsevier 2020-06-02 /pmc/articles/PMC7287142/ /pubmed/32551222 http://dx.doi.org/10.1016/j.rmcr.2020.101109 Text en © 2020 The Authors. Published by Elsevier Ltd. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Alkhunaizi, Ahmed M.
Al-Khouzaie, Thamer H.
Alsagheir, Ahmed I.
Sirolimus-induced interstitial lung disease and resolution after conversion to everolimus
title Sirolimus-induced interstitial lung disease and resolution after conversion to everolimus
title_full Sirolimus-induced interstitial lung disease and resolution after conversion to everolimus
title_fullStr Sirolimus-induced interstitial lung disease and resolution after conversion to everolimus
title_full_unstemmed Sirolimus-induced interstitial lung disease and resolution after conversion to everolimus
title_short Sirolimus-induced interstitial lung disease and resolution after conversion to everolimus
title_sort sirolimus-induced interstitial lung disease and resolution after conversion to everolimus
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7287142/
https://www.ncbi.nlm.nih.gov/pubmed/32551222
http://dx.doi.org/10.1016/j.rmcr.2020.101109
work_keys_str_mv AT alkhunaiziahmedm sirolimusinducedinterstitiallungdiseaseandresolutionafterconversiontoeverolimus
AT alkhouzaiethamerh sirolimusinducedinterstitiallungdiseaseandresolutionafterconversiontoeverolimus
AT alsagheirahmedi sirolimusinducedinterstitiallungdiseaseandresolutionafterconversiontoeverolimus